| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 01/17/2012 | CA2485852C Agent for binding a plurality of c-reactive protein and their use in the treatment and prevention of tissue damage |
| 01/17/2012 | CA2473986C Indazole compounds useful as protein kinase inhibitors |
| 01/17/2012 | CA2465007C Methods and means for producing proteins with predetermined post-translational modifications |
| 01/17/2012 | CA2451244C Purine derivatives as a2b adenosine receptor antagonists |
| 01/17/2012 | CA2441958C Il-28 polypeptides and polynucleotids |
| 01/17/2012 | CA2385456C 9-(piperazinylalkyl) carbazoles as bax-modulators |
| 01/17/2012 | CA2320371C Inotropic and diuretic effects of exendin and glp-1 |
| 01/12/2012 | WO2012006569A1 Methods for the prevention or treatment of no-reflow following ischemia/reperfusion injury |
| 01/12/2012 | WO2012006510A1 Fatty acid protein kinase c activators and anticoagulant for the treatment of stroke |
| 01/12/2012 | WO2012006500A2 Monoclonal antibodies against hepatitis c virus core protein |
| 01/12/2012 | WO2012006440A2 Endothelial cell production by programming |
| 01/12/2012 | WO2012006320A1 Photosensitive cardiac rhythm modulation systems |
| 01/12/2012 | WO2012006203A1 N-cyclyl-3 - (cyclylcarbonylaminomethyl) benzamide derivatives as rho kinase inhibitors |
| 01/12/2012 | WO2012006202A1 Rho kinase inhibitors |
| 01/12/2012 | WO2012005343A1 Substituted pyridine compound |
| 01/12/2012 | WO2012004900A1 Thienopyrimidine compounds |
| 01/12/2012 | WO2012004549A1 Phenoxypropanol derivatives and their use in treating cardiac and cardiovascular diseases |
| 01/12/2012 | WO2012004287A1 5-(biphenyl-4-yl)-3-phenyl-1,2,4-oxadiazolyl derivatives as ligands on the sphingosine 1-phosphate (s1p) receptors |
| 01/12/2012 | WO2012004259A1 Ring-fused 4 -aminopyrimidines and use thereof as stimulators of soluable guanylate cyclases |
| 01/12/2012 | WO2012004258A1 Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases |
| 01/12/2012 | WO2012004228A1 Use of glabranin for stimulating hair growth |
| 01/12/2012 | WO2012004227A1 Malvidin for promoting hair growth |
| 01/12/2012 | WO2012003811A1 C-aryl glucoside sglt2 inhibitors and method |
| 01/12/2012 | WO2012003802A1 Use of 5α-androstane (alkyl)-3β,5,6β-triol in preparing neuroprotective drugs |
| 01/12/2012 | WO2012003784A1 Pyrazine derivatives,process for manufacture and use thereof |
| 01/12/2012 | WO2012003554A2 Compositions and methods for removal or destruction of amyloid fibril or amyloid adhesin comprising aggregates |
| 01/12/2012 | WO2011112838A3 Composition and method for treatment of vascular hyperpermeability |
| 01/12/2012 | WO2011106525A9 Methods of treating cerebral amyloid angiopathy |
| 01/12/2012 | US20120010557 Drug Delivery System for Use in the Treatment of Vascular and Vessel-Related Pathologies |
| 01/12/2012 | US20120010295 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases |
| 01/12/2012 | US20120010292 Modification i of 4-(phenyl)ethyl]-amino}methyl)benzoic acid |
| 01/12/2012 | US20120010282 Tautomycetin and Tautomycetin Analog Biosynthesis |
| 01/12/2012 | US20120010273 Hybrid Hepatocyte Growth Factor Gene Having High Expression Efficiency of Two Heterotypes of Hepatocyte Growth Factor |
| 01/12/2012 | US20120010263 Acetylene derivatives having mglur 5 antagonistic activity |
| 01/12/2012 | US20120010258 Additional therapeutic use |
| 01/12/2012 | US20120010256 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 01/12/2012 | US20120010248 Mitochondrial Aldehyde Dehydrogenase-2 Modulators and Methods of Use Thereof |
| 01/12/2012 | US20120010247 Bicyclic compound |
| 01/12/2012 | US20120010243 Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
| 01/12/2012 | US20120010216 Pharmaceutical compositions containing vanoxerine |
| 01/12/2012 | US20120010213 Oral controlled release dosage forms for water soluble drugs |
| 01/12/2012 | US20120010203 Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments |
| 01/12/2012 | US20120010197 Protein kinase inhibitors |
| 01/12/2012 | US20120010192 Fused Heterocyclic Compounds as Ion Channel Modulators |
| 01/12/2012 | US20120010191 Pyridone and aza-pyridone compounds and methods of use |
| 01/12/2012 | US20120010188 Imidazopyridine Compounds |
| 01/12/2012 | US20120010185 New pyridone derivates with mch antagonistic activity and medicaments comprising these compounds |
| 01/12/2012 | US20120010181 Compounds for the treatment of inflammatory disorders |
| 01/12/2012 | US20120010177 MicroRNA Modulators and Method for Identifying And Using The Same |
| 01/12/2012 | US20120010172 Novel urea and thiourea derivatives |
| 01/12/2012 | US20120010156 Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1 |
| 01/12/2012 | US20120010138 Novel uses of vegfxxxb |
| 01/12/2012 | US20120010137 Use of ixolaris, a tissue factor inhibitor, for the treatment and prevention of cancer |
| 01/12/2012 | US20120010136 Use of cd31 peptides in the treatment of thrombotic and autoimmune disorders |
| 01/12/2012 | US20120010135 Spiro derivatives for the modulation of stearoyl-coa desaturase |
| 01/12/2012 | US20120010126 Recombinant surfactant protein d compositions and methods of use thereof |
| 01/12/2012 | US20120010123 Methods of treating metabolic disorders and cardiovascular diseases |
| 01/12/2012 | US20120009288 Use of acacia extracts and their compounds on inhibition of xanthine oxidase |
| 01/12/2012 | US20120009276 Composition for the treatment of oxidative stress |
| 01/12/2012 | US20120009271 Method of disease-induced and receptor-mediated stem cell neuroprotection |
| 01/12/2012 | US20120009269 Range of aseptically produced infant foods having low concentrations of undesired by-products and methods for making the same |
| 01/12/2012 | US20120009268 Modified Virus Vectors and Methods of Making and Using the Same |
| 01/12/2012 | US20120009259 Formulation for co-therapy treatment of diabetes |
| 01/12/2012 | US20120009257 Galenical Formulations of a Fixed Dose Combination of Valsartan and Aliskiren |
| 01/12/2012 | US20120009229 Pharmaceutical compositions and related methods of delivery |
| 01/12/2012 | US20120009226 Highly pure laquinimod or a pharmaceutically acceptable salt thereof |
| 01/12/2012 | US20120009196 Monoclonal antibodies against hepatitis c virus core protein |
| 01/12/2012 | US20120009195 Antibody neutralizers of human granulocyte macrophage colony stimulating factor |
| 01/12/2012 | US20120009184 Anti-C5 Alpha Antibodies |
| 01/12/2012 | US20120009174 Biomarkers for myocardial ischemia |
| 01/12/2012 | US20120009172 Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor |
| 01/12/2012 | US20120009166 Isolated monocyte populations and related therapeutic applications |
| 01/12/2012 | US20120009165 Blood-adiponectin-concentration increase-accelerator and/or decrease-inhibitor thereof and visceral fat accumulation inhibitor |
| 01/12/2012 | US20120009158 VENTRICULAR INDUCED PLURIPOTENT STEM (ViPS) CELLS FOR GENERATION OF AUTOLOGOUS VENTRICULAR CARDIOMYOCYTES AND USES THEREOF |
| 01/12/2012 | US20120009152 Nitric oxide donors for treatment of disease and injury |
| 01/12/2012 | DE102010031149A1 New 1H-pyrazolo(3,4-b)pyridine compounds are guanylate cyclase stimulators useful to treat and/or prevent heart failure, angina pectoris, hypertonia, pulmonary hypertonia, ischemia, and vascular disease |
| 01/12/2012 | DE102010031148A1 New 1-(2-fluoro-benzyl)-1H-pyrazolo(3,4-b)pyridine compounds are guanylate cyclase stimulators useful to treat and/or prevent heart failure, angina pectoris, hypertonia, pulmonary hypertonia, ischemia, and vascular disease |
| 01/12/2012 | CA2804924A1 Substituted pyridine compound |
| 01/12/2012 | CA2804789A1 Pkc activators and anticoagulant in regimen for treating stroke |
| 01/12/2012 | CA2804595A1 Endothelial cell production by programming |
| 01/12/2012 | CA2804473A1 5-(biphenyl-4-yl)-3-phenyl-1,2,4-oxadiazolyl derivatives as ligands on the sphingosine 1-phosphate (s1p) receptors |
| 01/12/2012 | CA2804471A1 Ring-fused 4 -aminopyrimidines and use thereof as stimulators of soluable guanylate cyclases |
| 01/12/2012 | CA2804470A1 Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases |
| 01/12/2012 | CA2804404A1 Methods for reducing oxidative damage |
| 01/12/2012 | CA2802133A1 Use of 5.alpha.-androstane(alkyl)-3.beta.,5,6.beta.-triol in preparation of neuroprotective drugs |
| 01/11/2012 | EP2405015A2 Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| 01/11/2012 | EP2404935A1 Immunoglobulin binding HOSM |
| 01/11/2012 | EP2404932A1 Polypeptides and antibacterial or antiseptic use of same |
| 01/11/2012 | EP2404918A1 Pyridine derivative |
| 01/11/2012 | EP2404895A1 Calixarene-based peptide conformation mimetics, methods of use, and methods of making |
| 01/11/2012 | EP2404603A1 Novel trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds for the treatment of CSBP/p38 kinase mediated diseases |
| 01/11/2012 | EP2404600A1 Use of the combination of a sinus current If inhibitor and an inhibitor of the angiotensin conversion enzyme for treating cardiac insufficiency |
| 01/11/2012 | EP2403848A1 Pharmaceutical hypocholesterolemic compositions |
| 01/11/2012 | EP2403847A1 Triazine derivatives as kinase inhibitors |
| 01/11/2012 | EP2403833A1 8-substituted quinolines and related analogs as sirtuin modulators |
| 01/11/2012 | EP2403498A2 Enhancing coagulation or reducing fibrinolysis |
| 01/11/2012 | EP2403492A1 Use of pyrimidylaminobenzamide derivatives for the treatment of disorders mediated by the leucine zipper- and sterile alpha motif-containing kinase (zak) |
| 01/11/2012 | EP2173735B1 Imidazole derivatives as ccr2 receptor antagonists |
| 01/11/2012 | EP2037928B1 Methods for treating atherosclerosis |
| 01/11/2012 | EP1948215B1 MacroH2A non-histone domain as inhibitor of PARP-1 activity and uses thereof |